NCT00008749Unknown不适用
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus
National Center for Research Resources (NCRR)1 个研究点 分布在 1 个国家开始时间: 2001年1月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 试验地点
- 1
研究概览
简要总结
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
入排标准
- 年龄范围
- 13 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus ErythematousSystemic Lupus ErythematousNCT02320357University Hospital, Bordeaux18
Unknown
不适用
New Signaling Pathway Targeting Systemic Lupus ErythematosusSLENCT03984227Assiut University60
撤回
2 期
Atacicept Demonstrating Dose RESponSeSystemic Lupus ErythematosusNCT01440231EMD Serono
Unknown
4 期
Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart DiseaseSystemic Lupus ErythematosusNCT00188188University Health Network, Toronto50
已完成
2 期
Low-dose Interleukin-2 for Treatment of Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03312335Onur Boyman, MD16
